TE9-28z-iTAG2 CAR T cells

TE9-28z-iTAG2 CAR T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to target B7-H3 (CD276), a glycoprotein frequently overexpressed in pediatric high-grade central nervous system (CNS) tumors. Developed by University College London (UCL) and the UCL Cancer Trials Centre in collaboration with Cancer Research UK, the construct utilizes the TE9 scFv for high-affinity binding to B7-H3, coupled with a second-generation CAR architecture featuring a CD28 costimulatory domain and a CD3-zeta activation domain. A distinctive feature of this therapy is the inclusion of the iTAG2 safety switch, which serves as both a marker for cell tracking and a mechanism for cell depletion to mitigate potential severe toxicities. The therapy is administered directly into the cerebrospinal fluid via an intracerebroventricular Ommaya reservoir, a strategy intended to bypass the blood-brain barrier and maximize the concentration of effector cells at the tumor site.

Other names

B7-H3 CAR T cellsB-7-H3 CAR T cellsB 7-H3 CAR T cellsTE9-28z-iTAG2TE-9-28z-iTAG2TE 9-28z-iTAG2